Podium to Practice: Chicago 2026 – LUNG: DeLLphi-304
OR
Studies / Trials Discussed
8006 – Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
8006 – Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.